Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
CRNX 
Crinetics Pharmaceuticals Inc (CRNX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
02/25/2026: CRNX (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
17 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $85
1 Year Target Price $85
| 11 | Strong Buy |
| 5 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 4.56B USD | Price to earnings Ratio - | 1Y Target Price 85 |
Price to earnings Ratio - | 1Y Target Price 85 | ||
Volume (30-day avg) 17 | Beta 0.19 | 52 Weeks Range 24.10 - 57.99 | Updated Date 02/24/2026 |
52 Weeks Range 24.10 - 57.99 | Updated Date 02/24/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.53 |
Earnings Date
Report Date 2026-03-04 | When - | Estimate -1.28 | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -99710.49% |
Management Effectiveness
Return on Assets (TTM) -28% | Return on Equity (TTM) -44.42% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 2762821510 | Price to Sales(TTM) 2973.18 |
Enterprise Value 2762821510 | Price to Sales(TTM) 2973.18 | ||
Enterprise Value to Revenue 1984.79 | Enterprise Value to EBITDA -13.4 | Shares Outstanding 102511840 | Shares Floating 87132534 |
Shares Outstanding 102511840 | Shares Floating 87132534 | ||
Percent Insiders 1.99 | Percent Institutions 121.62 |
Upturn AI SWOT
Crinetics Pharmaceuticals Inc
Company Overview
History and Background
Crinetics Pharmaceuticals Inc. was founded in 2017 with a mission to develop therapies for rare endocrine disorders. The company has rapidly advanced its pipeline through innovative research and strategic partnerships. A significant milestone was the successful completion of Phase 2 trials for its lead candidate, balgricap. The company is focused on addressing unmet medical needs in conditions like Cushing's disease and acromegaly.
Core Business Areas
- Endocrine Disorder Therapeutics: Crinetics Pharmaceuticals Inc. is dedicated to the discovery, development, and commercialization of novel therapeutics for rare endocrine disorders. This includes the development of small molecule drugs targeting specific hormonal pathways that are dysregulated in these conditions.
Leadership and Structure
Crinetics Pharmaceuticals Inc. is led by a seasoned management team with expertise in biotechnology, drug development, and commercialization. Specific leadership details, including the CEO, CFO, and heads of R&D and clinical operations, can be found on their corporate website and SEC filings. The company operates with a focused, integrated structure to expedite drug development.
Top Products and Market Share
Key Offerings
- Balgricap (CRN0001): Balgricap is an investigational oral somatostatin receptor 5 (SSTR5) antagonist developed for the treatment of endogenous Cushing's syndrome. Clinical trials have demonstrated its efficacy in reducing cortisol levels. Market share data is not yet applicable as the drug is in late-stage development. Competitors in the Cushing's syndrome space include Recordati (Isturisa) and HRA Pharma (Zoptarelin doxorubicin).
Market Dynamics
Industry Overview
The rare endocrine disorder therapeutics market is a niche but growing segment of the pharmaceutical industry. It is characterized by high unmet medical needs, significant scientific innovation, and a regulatory environment that often provides incentives for rare disease drug development. The market is driven by increasing diagnosis rates, advancements in genetic understanding, and the pursuit of targeted therapies.
Positioning
Crinetics Pharmaceuticals Inc. is positioned as an innovator in the rare endocrine disease space, focusing on developing first-in-class or best-in-class therapies. Its competitive advantage lies in its deep scientific understanding of hormonal pathways, its focused pipeline targeting significant unmet needs, and its experienced leadership team.
Total Addressable Market (TAM)
The total addressable market for rare endocrine disorders is substantial and growing, with specific sub-segments like Cushing's syndrome and acromegaly representing hundreds of millions to billions of dollars annually. Crinetics Pharmaceuticals Inc. is positioned to capture a significant portion of this TAM with its lead candidate, balgricap, and future pipeline developments.
Upturn SWOT Analysis
Strengths
- Focused pipeline on rare endocrine disorders with significant unmet needs.
- Experienced management team with a proven track record in drug development.
- Promising clinical data for lead candidate, balgricap.
- Potential for orphan drug designation and market exclusivity.
Weaknesses
- Early-stage company with limited commercialization experience.
- Reliance on the success of a single lead candidate.
- Need for substantial future funding for late-stage trials and commercial launch.
Opportunities
- Potential for significant market penetration in underserved rare disease areas.
- Expansion of pipeline into other rare endocrine disorders.
- Strategic partnerships or acquisition by larger pharmaceutical companies.
- Favorable regulatory pathways for rare disease treatments.
Threats
- Clinical trial failures or unexpected side effects.
- Competition from other companies developing similar therapies.
- Pricing pressures and reimbursement challenges.
- Changes in regulatory landscape.
Competitors and Market Share
Key Competitors
- Recordati (RCY)
- HRA Pharma (not publicly traded directly in US)
Competitive Landscape
Crinetics Pharmaceuticals Inc. competes in a landscape with established pharmaceutical companies and other emerging biotech firms. Its advantage lies in its targeted approach to specific rare endocrine disorders, aiming for potentially differentiated therapeutic profiles. The main disadvantage is its smaller size and reliance on a single key asset compared to larger, diversified competitors.
Growth Trajectory and Initiatives
Historical Growth: Crinetics Pharmaceuticals Inc.'s historical growth has been characterized by the advancement of its pipeline through preclinical and clinical development stages, securing significant funding rounds, and building its scientific and operational teams. Growth is measured by progress in R&D milestones rather than traditional revenue growth.
Future Projections: Future growth projections are contingent on the successful completion of clinical trials for balgricap, regulatory approval, and subsequent commercial launch. Analyst estimates would focus on potential peak sales for balgricap and the future value of its pipeline.
Recent Initiatives: Recent initiatives would include the progression of balgricap through clinical trials (e.g., Phase 3), potential regulatory submissions, and the exploration of new drug candidates or indications.
Summary
Crinetics Pharmaceuticals Inc. is a promising clinical-stage biotechnology company focused on rare endocrine disorders, with a lead drug candidate, balgricap, showing strong potential. Its strengths lie in its specialized focus and experienced team, while its weaknesses include its early stage and reliance on one drug. The company has significant opportunities for growth if it navigates clinical and regulatory hurdles successfully, but must remain vigilant of competitive threats and funding needs.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q, S-1)
- Company Investor Relations
- Industry Analyst Reports
- Financial Data Providers (e.g., Bloomberg, Refinitiv - data synthesized for this response)
Disclaimers:
This analysis is based on publicly available information and is intended for informational purposes only. It does not constitute financial advice. Investment decisions should be made after consulting with a qualified financial advisor and conducting independent research. Market share data for development-stage products is not yet established. Competitor information is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Crinetics Pharmaceuticals Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2018-07-18 | Founder, President, CEO & Director Dr. R. Scott Struthers Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 437 | Website https://www.crinetics.com |
Full time employees 437 | Website https://www.crinetics.com | ||
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in a Phase 3 clinical trial for the treatment of acromegaly and carcinoid syndrome associated with neuroendocrine tumors. It is also developing Atumelnant, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and cushing's disease; and CRN09682, a nonpeptide drug conjugate for SST2 positive solid tumors. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease; SST3 Agonist program for the treatment for autosomal dominant polycystic kidney disease; and Radionetics for multiple solid-tumors, as well as Oral GLP-1 and Oral GIP nonpeptides for the treatment of obesity. The company has an agreement with Sanwa Kagaku Kenkyusho Co., Ltd to develop and commercialize Paltusotine in Japan, and Cellular Longevity, Inc. to develop and commercialize CRN01941, a somatostatin receptor type 2 agonist. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.